Regulus Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Regulus Therapeutics is Jay Hagan, benoemd in May2017, heeft een ambtstermijn van 7.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.57M, bestaande uit 23.9% salaris en 76.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.087% van de aandelen van het bedrijf, ter waarde € 82.86K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 7.5 jaar.

Belangrijke informatie

Jay Hagan

Algemeen directeur

US$2.6m

Totale compensatie

Percentage CEO-salaris	23.9%
Dienstverband CEO	7.5yrs
Eigendom CEO	0.09%
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	7.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jay Hagan's beloning veranderd ten opzichte van Regulus Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$42m
Jun 30 2024	n/a	n/a	-US$35m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$3m	US$616k	-US$30m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$29m
Dec 31 2022	US$1m	US$598k	-US$28m
Sep 30 2022	n/a	n/a	-US$29m
Jun 30 2022	n/a	n/a	-US$30m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$2m	US$568k	-US$28m
Sep 30 2021	n/a	n/a	-US$22m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$16m
Dec 31 2020	US$2m	US$552k	-US$16m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$23m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$2m	US$536k	-US$19m
Sep 30 2019	n/a	n/a	-US$22m
Jun 30 2019	n/a	n/a	-US$27m
Mar 31 2019	n/a	n/a	-US$36m
Dec 31 2018	US$2m	US$520k	-US$49m
Sep 30 2018	n/a	n/a	-US$55m
Jun 30 2018	n/a	n/a	-US$60m
Mar 31 2018	n/a	n/a	-US$68m
Dec 31 2017	US$2m	US$475k	-US$72m

Compensatie versus markt: De totale vergoeding ($USD 2.57M ) Jay } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Jay is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jay Hagan (55 yo)

7.5yrs

Tenure

US$2,574,323

Compensatie

Mr. Joseph P. Hagan, also known as Jay, served as Independent Director of Zosano Pharma Corporation since May 22, 2015, until May 10, 2022. He has been the Chief Executive Officer and Director of Regulus T...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Hagan	CEO & Director	7.5yrs	US$2.57m	0.087% € 82.9k
Crispina Calsada	Chief Financial Officer	5.3yrs	US$1.07m	0.0088% € 8.4k
Christopher Aker	Senior VP	13.8yrs	US$1.09m	0.015% € 14.6k
Preston Klassen	President	1.4yrs	geen gegevens	0% € 0
Daniel Penksa	VP of Finance & Controller	5.3yrs	geen gegevens	geen gegevens
Claire Padgett	Senior Vice President of Clinical Operations	2yrs	geen gegevens	geen gegevens
Rekha Garg	Chief Medical Officer	2yrs	geen gegevens	geen gegevens
Edmund Lee	Vice President of Translational Medicine	no data	geen gegevens	geen gegevens

5.3yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 7RG0 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joseph Hagan	CEO & Director	7.5yrs	US$2.57m	0.087% € 82.9k
Preston Klassen	President	1.4yrs	geen gegevens	0% € 0
William Rastetter	Independent Director	11.6yrs	US$99.44k	0.060% € 56.7k
Timothy Wright	Member of the Scientific Advisory Board	5.7yrs	US$1.48m	geen gegevens
Stelios Papadopoulos	Independent Chairman of the Board	15.8yrs	US$131.44k	1.49% € 1.4m
David Baltimore	Chairman of the Scientific Advisory Board & Independent Director	15.8yrs	US$95.44k	0.0039% € 3.7k
Jason Nunn	Independent Director	5.4yrs	US$97.44k	0% € 0
Thomas Tuschl	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Markus Stoffel	Member of the Scientific Advisory Board	no data	geen gegevens	geen gegevens
Hugh Rosen	Independent Director	8.4yrs	US$93.44k	0.0027% € 2.6k
Kathryn Collier	Independent Director	6.6yrs	US$107.44k	0.010% € 9.8k
Pascale Witz	Independent Director	7.4yrs	US$93.44k	0.0072% € 6.9k

7.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 7RG0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).

Regulus Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

Insufficient new directors

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Recent updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Rgls8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

New minor risk - Profitability

New major risk - Revenue and earnings growth

Regulus Therapeutics Inc. Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Bio-Techne Corporation and Regulus Therapeutics Inc. Announces Continued Technical and Clinical Collaboration

Regulus Therapeutics Inc. Announces Promotion of Rekha Garg to Chief Medical Officer

Regulus Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Regulus Therapeutics Inc., Annual General Meeting, May 16, 2024

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors

Regulus Therapeutics Inc. announced that it expects to receive $100 million in funding from a group of investors

Insufficient new directors

Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1B Multiple Ascending Dose (Mad) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (Madpkd)

New major risk - Financial position

Regulus Therapeutics, Inc. Announces First Patient Dosed in Second Cohort of Phase 1b Multiple Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Preston S. Klassen to President and Head of Research and Development

Regulus Therapeutics Advances to Cohort 2 of Phase 1B Multiple-Ascending Dose Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Resignation of Simos Simeonidis as Board Member

Regulus Therapeutics Inc. Announces Executive Changes

Insufficient new directors

Regulus Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Regulus Therapeutics Inc. Announces First Patient Dosed in Phase 1B Multiple-Ascending Dose Clinical Trial of RGSL8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces Positive Topline Safety and Pharmacokinetic Data from the Phase 1 Single-Ascending Dose (Sad) Clinical Trial of Rgls8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022

Insufficient new directors

Insufficient new directors

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Announces First Subject Dosed in Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. Announces FDA Acceptance of Investigational New Drug Application for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Regulus Therapeutics Inc. to Report Q4, 2021 Results on Mar 10, 2022

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

Regulus Therapeutics Inc. Announces Successful Completion of Pre-Ind Meeting with FDA for Rgls8429

Regulus Therapeutics Inc. announced that it has received $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

Regulus Therapeutics Inc. to Present Additional Data from Its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program At PKD Connect 2021

Regulus Therapeutics Inc. Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease Program

Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Full year 2020 earnings released: US$0.45 loss per share (vs US$1.08 loss in FY 2019)

Revenue beats expectations

New 90-day high: €1.58

Regulus Therapeutics Inc. Announces Completion of Enrollment in First Cohort of Phase 1B Clinical Trial of Rgls4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics Inc. Appoints Alice S. Huang to the Board of Directors

New 90-day high: €1.32

New 90-day high: €0.84

Regulus Therapeutics Collaborates with Bio-Techne Corporation for Biomarker Development

Regulus Therapeutics Inc. announced that it expects to receive $19.091813 million in funding

New 90-day high: €0.52

Revenue beats expectations

Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

New 90-day low - €0.38

New 90-day low - €0.53

First half earnings released

New 90-day high - €0.84

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd